Skip to content
Clinical Trials for Alzheimer's Disease

Miami, Florida

Alzheimer's disease clinical trials in Miami, FL

24 Alzheimer's disease studies are recruiting participants at sites in Miami as of November 16, 2026, according to ClinicalTrials.gov. Clinical Trials for Alzheimer's Disease can help you understand your options and connect with a study team.

Call (888) 927-5895
  • No cost to ask
  • Taking part is voluntary
  • Studies are independently reviewed

Miami at a glance

  • 24 studies are recruiting at a site in Miami.
  • By phase: Phase 2 (8), Phase 2/3 (1), Phase 3 (7), Phase 4 (1), No phase (3), Observational (4). Studies of devices and behavioral approaches have no phase.
  • By sponsor: industry (19), university, hospital or other (5).
  • Most recent update to one of these records: November 16, 2026.

Studies recruiting in Miami

Basic details from each study's public record. Select a study to read the full record on ClinicalTrials.gov, including how to contact its team.

  1. Screening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease Studies

    • Phase 3
    • Ages 50 to 90
    • All sexes
    Sponsor
    Hoffmann-La Roche
    Study site
    Visionary Investigators Network- Neurology Aventura
    Registry record
    NCT07177352 · updated
  2. Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3)

    • Phase 3
    • Ages 55 to 90
    • All sexes
    Sponsor
    Karuna Therapeutics, Inc., a Bristol Myers Squibb company
    Study sites
    A & D Doctor Center · Allied Biomedical Research Institute · Angels Clinical Research Institute - Miami
    Registry record
    NCT05980949 · updated
  3. A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Alzheimer's Disease Psychosis

    • Phase 2
    • Ages 55 to 90
    • All sexes
    Sponsor
    MapLight Therapeutics
    Registry record
    NCT06887192 · updated
  4. A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3)

    • Phase 3
    • Ages 55 to 90
    • All sexes
    Sponsor
    Bristol-Myers Squibb
    Study site
    Nuovida Research Center
    Registry record
    NCT06937229 · updated
  5. ACP-204 in Adults With Alzheimer's Disease Psychosis

    • Phase 2/3
    • Ages 55 to 95
    • All sexes
    Sponsor
    ACADIA Pharmaceuticals Inc.
    Study sites
    ABBA Medical Group LLC · Advanced Clinical Research Network, Corp · Future Care Solution, LLC
    Registry record
    NCT06159673 · updated
  6. Flutemetamol F 18 Injection Formulation Comparison

    • Phase 2
    • Ages 50 to 110
    • All sexes
    Sponsor
    GE Healthcare
    Study site
    Visionary Investigator Network
    Registry record
    NCT07873463 · updated
  7. A Study of Donanemab (LY3002813) in Participants With Early Cognitive Decline (TRAILBLAZER-ALZ 7)

    • Phase 2
    • Ages 55 to 85
    • All sexes
    Sponsor
    Eli Lilly and Company
    Study site
    BRP-Kendal Lakes
    Registry record
    NCT07589595 · updated
  8. A Study to Assess the Efficacy and Safety of ITI-1284 in the Treatment of Psychosis Associated With Alzheimer's Disease

    • Phase 2
    • Ages 55 and older
    • All sexes
    Sponsor
    Intra-Cellular Therapies, Inc.
    Study sites
    Allied Biomedical Research Institute (ABRI), Inc · South Florida Research Phase I-IV · Sunshine Medical Solution
    Registry record
    NCT06540833 · updated
  9. A Study to Assess the Efficacy and Safety of ITI-1284 in the Treatment of Agitation Associated With Alzheimer's Dementia

    • Phase 2
    • Ages 55 and older
    • All sexes
    Sponsor
    Intra-Cellular Therapies, Inc.
    Study sites
    Advanced Clinical Research Network · Allied Biomedical Research Institute (ABRI), Inc · South Florida Research Phase I-IV
    Registry record
    NCT06651567 · updated
  10. A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease

    • Phase 3
    • Ages 55 to 90
    • All sexes
    Sponsor
    Bristol-Myers Squibb
    Study site
    Miami Jewish health
    Registry record
    NCT07011745 · updated
  11. A Study of Donanemab (LY3002813) in Participants Who Completed Study AACM (TRAILBLAZER-ALZ 3-EXT).

    • Phase 3
    • Ages 55 and older
    • All sexes
    Sponsor
    Eli Lilly and Company
    Study sites
    Finlay Medical Research · VIN-Andrew Lerman
    Registry record
    NCT07602582 · updated
  12. Combating Alzheimer's Through Sleep and Exercise

    • No phase
    • Ages 55 to 80
    • All sexes
    Sponsor
    University of Miami
    Study site
    University of Miami Hospitals
    Registry record
    NCT04855630 · updated
  13. [18F]PI-2620 Phase 3 Histopathological Study

    • Phase 3
    • Ages 50 and older
    • All sexes
    Sponsor
    Lantheus Biosciences Ltd.
    Study site
    Miami Jewish Health Systems
    Registry record
    NCT05641688 · updated
  14. Personalized Obstructive Sleep Apnea Treatment and Effects on Alzheimer's Disease Biomarkers and Cognition Among Blacks

    • No phase
    • Ages 55 to 85
    • All sexes
    Sponsor
    University of Miami
    Study site
    University of Miami
    Registry record
    NCT06089161 · updated
  15. A Study of Zunveyl on Safety, Tolerability, Neuropsychiatric Symptoms, and Caregiver Distress in Alzheimer's Disease (RESOLVE)

    • Phase 4
    • Ages 50 and older
    • All sexes
    Sponsor
    Alpha Cognition, Inc
    Study sites
    Allied Biomedical Research Institute (ABRI), Inc · CCM Clinical Research Group, LLC
    Registry record
    NCT07633470 · updated
  16. Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant

    • Phase 3
    • Ages 18 to 75
    • All sexes
    Sponsor
    Eidos Therapeutics, a BridgeBio company
    Study site
    University of Miami
    Registry record
    NCT06563895 · updated
  17. Human Mesenchymal Stem Cells (hMSC) in Behavioral Problems Due to Alzheimer's Disease.

    • Phase 2
    • Ages 55 to 90
    • All sexes
    Sponsor
    Bernard (Barry) Baumel
    Study site
    University of Miami Department of Neurology
    Registry record
    NCT06781333 · updated
  18. Human Mesenchymal Stem Cells & Monoclonal Antibodies in the Treatment for Mild Cognitive Impairment or Early Alzheimer's Disease.

    • Phase 2
    • Ages 55 to 90
    • All sexes
    Sponsor
    Bernard (Barry) Baumel
    Study site
    University of Miami Department of Neurology
    Registry record
    NCT07512362 · updated
  19. Late Onset Alzheimer's Disease

    • Observational
    • Ages 55 and older
    • All sexes
    Sponsor
    Columbia University
    Study site
    University of Miami
    Registry record
    NCT05010603 · updated
  20. Development of a Database to Investigate Digital and Blood-Based Biomarkers and Their Relationship to Tau and Amyloid PET Imaging in Older Participants Who Are Cognitively Normal (CN), Have Mild Cognitive Impairment (MCI), or Have Mild-to-Moderate AD Dementia

    • Observational
    • Ages 60 to 90
    • All sexes
    Sponsor
    GAP Innovations, PBC
    Study site
    Visionary Investigators Network
    Registry record
    NCT06584357 · updated
  21. Open-label Extension Study in Participants With Early Alzheimer's Disease

    • Phase 2
    • Ages 50 to 85
    • All sexes
    Sponsor
    GlaxoSmithKline
    Study site
    GSK Investigational Site
    Registry record
    NCT07105709 · updated
  22. ExAblate Blood-Brain Barrier (BBB) Disruption for the Treatment of Alzheimer's Disease

    • No phase
    • Ages 50 to 85
    • All sexes
    Sponsor
    InSightec
    Study site
    Baptist Health South Florida & Florida International University
    Registry record
    NCT03671889 · updated
  23. Alzheimer's Disease Treatment With Combination of 40Hz Light and Cognitive Therapy

    • Observational
    • Ages 50 and older
    • All sexes
    Sponsor
    Alzheimer's Light LLC
    Study site
    Andrey Vyshedskiy
    Registry record
    NCT03657745 · updated
  24. Longitudinal Cognitive Assessment by BoCA

    • Observational
    • Ages 50 and older
    • All sexes
    Sponsor
    Alzheimer's Light LLC
    Study site
    Andrey Vyshedskiy
    Registry record
    NCT04114994 · updated

Source: ClinicalTrials.gov. Data processed . See every Alzheimer's disease study recruiting in Miami, FL on ClinicalTrials.gov.

Ask about studies near Miami

Tell us what you are looking for and a coordinator will contact you to talk through your options. Asking does not commit you to anything.

How should we reach you?
Add a message or the best time to reach you (optional)

Please do not include detailed medical information.

Before you contact a study

More locations in Florida

About these listings

These listings come from ClinicalTrials.gov, the study registry run by the U.S. National Library of Medicine. The data were processed on November 16, 2026. We show part of each public record (its title, phase, sponsor, basic eligibility and sites in this area) exactly as registered, and we group studies by place. Nothing in a record is reworded.

Clinical Trials for Alzheimer's Disease does not run these studies and is not affiliated with their sponsors. A listing is not a recommendation, and only a study's own team can tell you whether you may be eligible. Follow the link on any study to read its full record and contact that team directly, or ask us and a coordinator will help you understand your options. How we source and check what we publish.

Sources and further reading

Ask about a study

A coordinator will contact you. Asking does not commit you to anything.

Call (888) 927-5895

or send a short form

How should we reach you?

Call